Exten Industries

Repost of message from Ragingbull.com EXTI message board
Written by alandail

Exten Industries (EXTI) overview 

Thanks to better understanding on my part and feedback I've received,
I've completely rewritten this. Any additional feedback to make this
clearer would be appreciated.

The Exten Industries business is built around a revolutionary liver
cell lines they have developed and patented. These offer many
significant advantages, including they are:

1 - human (as opposed to porcine) 
2 - nontumorigenic (non-cancerous, as opposed to other's cancerous
human cell lines)
3 - immortilized (The ability of a genetically engineered cell line to
reproduce indefinitely)
4 - fully-functional (as discovered by Pfizer & now, Roche, & as
opposed to others, which aren't)
5 - readily available (as opposed to porcine, rat or human liver
"slices")
6 - cost-effective (as opposed to porcine, rat or human liver
"slices")

These cell lines have been validated by both Pfizer and
Hoffman-LaRoche - Pfizer signed a 15 year license after their
evaluation, it remains to be seen what Hoffman-LaRoche will do as they
just presented on wednesday. These cell lines are enabling EXTI to
enter, and possibly dominate 4 major markets - I'm listing these in
the order I think they will be able to enter the respective markets.

1 - the $3.7 billion Hepatocyte Test Kit market through their
MultiCell subsidiary. Through their world wide marketing and
distribution agreement with XenoTech has these test kits on the market
today, with their product launch at the ISSX Meeting beginning Oct 12,
2003. Many expect this cell line to become the gold standard for this
market. Their contract with XenoTech has already resulted in a 1.5
million payment, guarantees a minimum of $18 million in royalties over
7 years. Both numbers are enough to make EXTI profitable and it is
expected the actual numbers will far exceed these guaranteed amounts.

2 - the $43 billion Therapeutic Protein Production market through
their MultiCell subsidiary. Being fully functional liver cells, they
can generate therapeutic proteins with high yield and low cost vs.
current methods.

3 - the $2 billion bioartificial liver market through their Xenogenics
subsidiary. Think of it as dialysis for the liver. Again, these fully
functional immortalized liver cell lines give EXTI a major advantage
in this market.

4 - the $78 billion Liver Stem Cell Transplantation market. The holy
grail of liver research - be able to regenerate damaged liver tissue.

For more information, see 

http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=5678 
http://exti.info/ 
http://exten.com/ 
http://finance.yahoo.com/q/is?s=EXTI.OB